Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 26 articles: HTML format Text format

Single Articles

July 2018
1. BARNETT R
   Liver cirrhosis.
   Lancet. 2018;392:275.
   PubMed     Text format    
   
   
   May 2018
2. GARCIA-TSAO G
   Long-term albumin in cirrhosis: is it the ANSWER?
   Lancet. 2018 May 31. pii: S0140-6736(18)30948.
   PubMed     Text format    
   
   
   
3. CARACENI P, Riggio O, Angeli P, Alessandria C, et al
   Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
   Lancet. 2018 May 31. pii: S0140-6736(18)30840.
   PubMed     Text format     Abstract available
   
   
   March 2018
4. HARRISON SA, Rinella ME, Abdelmalek MF, Trotter JF, et al
   NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
   Lancet. 2018 Mar 5. pii: S0140-6736(18)30474.
   PubMed     Text format     Abstract available
   
   
   February 2018
5. KUDO M, Finn RS, Qin S, Han KH, et al
   Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
   Lancet. 2018 Feb 9. pii: S0140-6736(18)30207.
   PubMed     Text format     Abstract available
   
   
   January 2018
6. PATTEN DA, Shetty S
   Chronic liver disease: scavenger hunt for novel therapies.
   Lancet. 2018;391:104-105.
   PubMed     Text format    
   
   
   
7. FORNER A, Reig M, Bruix J
   Hepatocellular carcinoma.
   Lancet. 2018 Jan 4. pii: S0140-6736(18)30010.
   PubMed     Text format     Abstract available
   
   
   April 2017
8. WORNS MA, Galle PR
   Immune oncology in hepatocellular carcinoma-hype and hope.
   Lancet. 2017 Apr 20. pii: S0140-6736(17)31044.
   PubMed     Text format    
   
   
   
9. EL-KHOUEIRY AB, Sangro B, Yau T, Crocenzi TS, et al
   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
   Lancet. 2017 Apr 20. pii: S0140-6736(17)31046.
   PubMed     Text format     Abstract available
   
   
   February 2017
10. HEGADE VS, Kendrick SF, Dobbins RL, Miller SR, et al
    Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Lancet. 2017 Feb 7. pii: S0140-6736(17)30319.
    PubMed     Text format     Abstract available
    
    
    January 2017
11. SOTIROPOULOS GC, Machairas N, Kostakis ID, Kouraklis G, et al
    The struggle for intensive care coverage after hepatic resections: the Greek reality.
    Lancet. 2017;389:364-365.
    PubMed     Text format    
    
    
    December 2016
12. BRUIX J, Qin S, Merle P, Granito A, et al
    Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2016 Dec 5. pii: S0140-6736(16)32453.
    PubMed     Text format     Abstract available
    
    
    
13. NAULT JC
    The end of almost 10 years of negative RCTs in advanced hepatocellular carcinoma.
    Lancet. 2016 Dec 5. pii: S0140-6736(16)32480.
    PubMed     Text format    
    
    
    November 2016
14. KIRBY T
    Profile: The Kirby Institute celebrates 30 years.
    Lancet. 2016;388:2466.
    PubMed     Text format    
    
    
    October 2016
15. MAO X, Yan C, Li Y, Lin Y, et al
    Pharmacological mechanisms of Euphorbia Pekinensis and Glycyrrhiza acting on hepatocellular carcinoma ascites: a preclinical study.
    Lancet. 2016;388 Suppl 1:S93.
    PubMed     Text format     Abstract available
    
    
    
16. YANG X, Yu D, Ren Y, Wei J, et al
    EPB41, a novel hepatoma susceptibility gene dysregulated by c-Myc: an integrative functional genomics study.
    Lancet. 2016;388 Suppl 1:S89.
    PubMed     Text format     Abstract available
    
    
    
17. ZHANG YF, Shi M, Guo RP
    A novel risk score (MCCT) to guide decision for treatment of advanced hepatocellular carcinoma with transarterial chemoembolisation: a derivation and validation study.
    Lancet. 2016;388 Suppl 1:S35.
    PubMed     Text format     Abstract available
    
    
    August 2016
18. POWELL LW, Seckington RC, Deugnier Y
    Haemochromatosis.
    Lancet. 2016;388:706-16.
    PubMed     Text format     Abstract available
    
    
    June 2016
19. NEWSOME PN, Armstrong MJ, Gaunt P
    Liraglutide for patients with non-alcoholic steatohepatitis - Authors' reply.
    Lancet. 2016;387:2379.
    PubMed     Text format    
    
    
    
20. DALE A, Hartley P, Heneghan C
    Liraglutide for patients with non-alcoholic steatohepatitis.
    Lancet. 2016;387:2378.
    PubMed     Text format    
    
    
    
21. GABORIT B, Darmon P, Ancel P, Dutour A, et al
    Liraglutide for patients with non-alcoholic steatohepatitis.
    Lancet. 2016;387:2378-9.
    PubMed     Text format    
    
    
    May 2016
22. BRIERLEY R, Bosurgi R
    Gastroenterology and hepatology: a call for papers.
    Lancet. 2016;387:1889-1890.
    PubMed     Text format    
    
    
    March 2016
23. CORRIGAN M, Alrubaiy L, China L
    Hepatology training in the UK.
    Lancet. 2016;387:1055.
    PubMed     Text format    
    
    
    November 2015
24. WONG VW, Wong GL
    A LEAN treatment for non-alcoholic steatohepatitis.
    Lancet. 2015 Nov 19. pii: S0140-6736(15)00982.
    PubMed     Text format    
    
    
    
25. ARMSTRONG MJ, Gaunt P, Aithal GP, Barton D, et al
    Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
    Lancet. 2015 Nov 19. pii: S0140-6736(15)00803.
    PubMed     Text format     Abstract available
    
    
    October 2015
26. BERNAL W, Jalan R, Quaglia A, Simpson K, et al
    Acute-on-chronic liver failure.
    Lancet. 2015;386:1576-87.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: